Latest Hospitality News

Osteopore Limited reported a 30% year-on-year revenue increase in Q4 CY25, overcoming a slowdown in South Korea, and secured a strategic five-year partnership with DKSH Malaysia to expand its dental product reach.

Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.

Medical Developments International has posted positive operating cashflow for the first half of FY26, driven by robust growth in its flagship product Penthrox across Australia and Europe, alongside progress in paediatric approvals.

Micro-X Ltd has secured a historic $3.3 million order for its Rover mobile X-ray units in Malaysia, alongside a $6.2 million capital raise to fuel its expanding medical imaging and security technology pipeline.

Skin Elements Limited has marked a pivotal quarter with a $2.5 million capital raise and successful product evaluations, setting the stage for commercial rollout of its natural biotechnology range in 2026.

Decidr AI Industries has solidified its position in the agentic AI market by completing strategic acquisitions and launching its DecidrOS platform, achieving a 60% revenue increase in the December quarter.

CurveBeam AI reported steady progress in Q2 FY26 with five new device purchase orders, a $4 million milestone payment pending receipt, and key regulatory submissions underway in the US and China.

CurveBeam AI reported steady device orders alongside a $4 million milestone payment from its China commercialisation deal, while progressing FDA clearance and robotic surgery system validation.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

Cyclopharm has launched a pioneering clinical study combining its Technegas imaging with AI analysis to explore a novel treatment for severe COPD, potentially expanding care options for millions.

ImpediMed reported a solid Q2 FY26 with $3.9 million in revenue and significant reimbursement gains for its lymphoedema technology, while launching new US Heart Health and Wellness initiatives.

Patrys Limited has acquired Reliis, gaining a promising injectable formulation of quetiapine aimed at treating delirium with a rapid FDA approval pathway. This move positions Patrys at the forefront of addressing a significant unmet medical need in critical care.